HRTX

Heron Therapeutics Inc

Add to Watchlist

Advanced Chart

2.340

+0.010(+0.430%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

2.420

Open

2.360

VWAP

2.38

Vol

1.17M

Mkt Cap

356.45M

Low

2.305

Amount

2.80M

EV/EBITDA(TTM)

Total Shares

150.65M

445.34M

EV/OCF(TTM)

P/S(TTM)

2.46

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF, HTX-019, and HTX-034. HTX- ZYNRELEF is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting in adults. HTX-034 is a product candidate for postoperative pain management.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

39.52M

+20.44%

-0.010

-66.67%

38.25M

+6.18%

-0.010

-83.33%

37.42M

+7.92%

-0.010

-50%

Estimates Revision

The market is revising Downward the revenue expectations for Heron Therapeutics, Inc. (HRTX) for FY2025, with the revenue forecasts being adjusted by -0.78% over the past three months. During the same period, the stock price has changed by 35.26%.

Revenue Estimates for FY2025

Revise Downward

-0.78%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+35.26%

In Past 3 Month

2 Analyst Rating

177.78% Upside

Wall Street analysts forecast HRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRTX is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

177.78% Upside

Current: 2.340

Low

4.00

Averages

6.50

High

9.00

177.78% Upside

Current: 2.340

Low

4.00

Averages

6.50

High

9.00

Needham

Serge Belanger

Strong Buy

Reiterates

2025-04-11

Reason

Needham

Serge Belanger

Price Target

2025-04-11

Reiterates

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

2025-02-28

Reason

Needham

Serge Belanger

Price Target

2025-02-28

Reiterates

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

2024-12-04

Reason

Needham

Serge Belanger

Price Target

2024-12-04

Reiterates

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Maintains

$5 → $4

2024-11-13

Reason

Needham

Serge Belanger

Price Target

$5 → $4

2024-11-13

Maintains

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

2024-09-25

Reason

Needham

Serge Belanger

Price Target

2024-09-25

Reiterates

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

2024-08-07

Reason

Needham

Serge Belanger

Price Target

2024-08-07

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Heron Therapeutics Inc (HRTX.O) is -77.67, compared to its 5-year average forward P/E of -12.74. For a more detailed relative valuation and DCF analysis to assess Heron Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.74

Current PE

-77.67

Overvalued PE

3.31

Undervalued PE

-28.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.38

Current EV/EBITDA

1.50

Overvalued EV/EBITDA

4.10

Undervalued EV/EBITDA

-10.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.86

Current PS

2.23

Overvalued PS

11.03

Undervalued PS

0.69